Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Congress & Expo on Healthcare IT Paris, France.

Day 1 :

OMICS International Healthcare IT 2018 International Conference Keynote Speaker Jan Jacques Michiels photo

Prof. Dr. J. J. Michiels Multidisciplinairy Internist Blood Coagulation & Vascular Medicine Center, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, NL, Professor of Nature Medicine & Health Clinical and Molecular Genetics Blood & Coagulation Research, University Hospitals Antwerp, Brussels and Martin-Bratislava International Consultant Bloodcoagulation & Vascular Medicine Consultant Academic, Pharmaceutical and Industrial Medicine Editor Journal of Hematology & Thromboembolic Diseases, Editor World Journal of Hematology, Editor in Chief World Journal of Clinical Cases.



The JAK2 V617F mutated trilinear myeloproliferative neoplasms (MPN) include a broad spectrum of clinical laboratory and bone marrow features in essential thrombocythemia (ET), prodromal polycythemia vera (PV) and erythrocythemic PV, classical PV and advanced stages of masked PV and PV complicated by splenomegaly and secondary myelofibrosis (MF). Heterozygous JAK2 V617F mutated ET is associated with low JAK2 allele and MPN disease burden and normal life expectance. In combined heterozygous and homozygous or homozygous JAK2 V617F mutated trilinear MPN, the JAK2 mutation load increases from less than 50% in prodromal and early stage PV to above 50% up to 100%in classical PV, advanced PV and PV with MF. Bone marrow histology of megakaryocytes with various degrees of of eryhrocytic, megakaryocytic and granulocytic (EMG) myeloproliferation in JAK2 V617F mutated trilinear MPN clearly differ from monolinear megakaryocytic (M) or dual megakaryocytic granulocytic (MG) myeloproliferation in MPL or calreticulin (CALR) mutated thrombocythemia without features of PV. The morphology of clustered large pleomorphic megakaryocytes with hyperlobulated nuclei are similar in JAK2 V67F thrombocythemia, prodromal PV and classical PV patients. Monolinear megakaryocytic (M) myeloproliferation of large to giant megakaryocytes with hyperlobulated staghorn like nuclei is the hallmark of MPL 515 mutated normocellular thrombocythemia. CALR mutated thrombocythemia usually presents with high platelet count around 1000x10 9 /l and normocellular megakaryocytic (M) proliferation of immuture megakaryocytes with socalled cloud-like hyperchromatic nuclei followed

by dual megakaryocytic granulocytic (MG) myeloproliferation followed by various degrees of bone marrow fibrosis. Natural history and life expectancy are related to the degree of anemia, splenomegaly, myelofibrosis, constitutional symptoms. The acquisition of epigenetic mutations at increasing age independently on top of MPN disease burden predict unfavorable outcome in JAK2 V617F , MPL 515 and CALR mutated myeloproliferative neoplasms (MPNs, which mutually exclude each other.


Keynote Forum

Marko Kesti

Research director at Lapland University,Finland

Keynote: Continuous employee Quality of Working Life inquiry gamifies leadership development

Time : 09:40-10:20

OMICS International Healthcare IT 2018 International Conference Keynote Speaker Marko Kesti photo

Marko Kesti has M.Sc. at engineering, Dr. at social sciences and Adjunct professor specialized at human capital productivity. Kesti is research director at Lapland University. He has created new scientifically approved theories and tools for analyzing human capital productivity. Kesti is member of Finnish non-fiction writers with five books and is famous lecturer at his specialty.          



Staff is not only a cost; as an investment, it may form a competitive advantage. When companies start implementing continuous performance management, they need effective feedback tools. This is especially important at fast changing environment and service oriented work, which are characteristics for example at healthcare organizations. Line-managers tend to be process oriented; aiming to maximize the operative work, but the organization is a system that requires human oriented leadership approach to make long-term competitive advantages. Motivational issues are as important as operative work issue, but more difficult to detect. Supervisors’ need timely information about the possible problems because unsolved problems will eventually reduce both wellbeing and profit. To do this effectively there are needed sophisticated methods and tools, which goes way beyond annual staff surveys.

Traditional staff surveys use statistical analyzing, which is fundamentally wrong and tends to hide the development potential. These surveys are too long and done too seldom. New scientific method solves this problem – it is called the Quality of Working Life index (QWL) and it enables effective continuous feedback tool. Human performance is combination of all self-esteem factors which are Physical and emotional safety, Collaboration and identity and Objectives and creativity; therefore, single factor correlations are not reliable. Continuous QWL survey has six inquiry questions per month – two questions for each self-esteem category. QWL-index is reliable performance measurement and self-esteems guide supervisors to select optimal leadership practices. Continuous staff QWL-survey will gamify leadership and gain significant economical and customer value.


OMICS International Healthcare IT 2018 International Conference Keynote Speaker Srivatsan Sridhar photo

Dr. Srivatsan has completed his MBBS, FCCE( Endocrinology), PGP( Cardiology), C. Diab, MBA with more than 10+ years as a Clinician, Senior Medical Advisory & Senior Leadership roles. Currently, as a Chief Operating Officer & Head of Transformation for a 250 bedded hospital at Aster Sanad Hospital, Riyadh. Other role as a Group Corporate Strategist @ Aster DM Healthcare, a C-suite/Executive Director suite role for Global Strategies, Frugal innovations, Group Annual operating plan, Medical & Scientific affairs etc.

Dr. Rajasree S has MBBS, MD, MRCPCH(UK), FPEM and working as a Consultant Pediatrician @ Motherhood & Prashanth Hospitals, Chennai, India



Artificial Intelligence(AI), Big data & Predictive Analytics in healthcare is catching up in the west but developing countries are yet to evolve fully on these vistas. I would bring across 3 case scenarios of my contributions in transforming the Healthcare ecosystem through futuristic smart health technologies and frugal innovations in India.

AI in healthcare in India with Tricog, a start-up AI collaboration and roll-out of Tele-ECGs. Efficient Hub and spoke model plugged-in with smart ECG devices across 20 locations-- Picked up new 1000+ cardiac cases in 6 months project of surrounding rural districts, saving 163+ lives—A paradigm shift in healthcare from "Time is money" to "Time is life" in Heart attacks.

During my stint at Abbott Laboratories, we had worked on cost-effective disruptive healthcare innovations by launching a first of its kind Point of Care device Thyroid instant screening device in India, and had conducted over 5,600 camps, screening more than 2.4 Lakh patients. Prevalence in India who have hypothyroidism, is 10%. As a team, entered the Limca Book of Records for ‘Mission Thyroid Awareness Campaign’.

A primordial prevention, to decipher health begins way ahead in childhood and targeted health school screening as a part of School Health of 20,000 students, got devised. A health-pod in every school tagged to a Tertiary hospital with electronic health data & smart integrated health screening devices and capturing 2% of the disease burden. This adds testimony to the fact that a healthier nation demands effective tools for a sustainable care model, covering vast geographies.     



Keynote Forum

Jan Jacques Michiels

University Hospitals Antwerp and Brussels, Belgium and Goodheart Institute Rotterdam Netherlands

Keynote: Evaluation of classical and novel von Willebrand factor assays in von Willebrand disease patients

Time : 11:15-11:55

OMICS International Healthcare IT 2018 International Conference Keynote Speaker Jan Jacques Michiels photo


Prof. Dr. J. J. Michiels Multidisciplinairy Internist Blood Coagulation & Vascular Medicine Center, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, NL, Professor of Nature Medicine & Health Clinical and Molecular Genetics Blood & Coagulation Research, University Hospitals Antwerp, Brussels and Martin-Bratislava International Consultant Bloodcoagulation & Vascular Medicine Consultant Academic, Pharmaceutical and Industrial Medicine Editor Journal of Hematology & Thromboembolic Diseases, Editor World Journal of Hematology, Editor in Chief World Journal of Clinical Cases.



Background: A complete set of von Willebrand factor (VWF) assays is used for the diagnosis and classification of von Willebrand disease (VWD) according to European Clinical Laboratory and Molecular (ECLM) criteria (Clinical Applied Thrombosis/Hemostasis 2017;23(6):518).


Aims: We critically evaluated the von Willebrand factor (VWF) assays VWF:GPIbM and VWF:GPIbR in von Willebrand disease (VWD) against the use of ECLM criteria as the gold standard for VWD classification anno 2018.


Methods: The complete set of VWF assays include Platelet Function Analyser closure time (PFA-CT) von Willebrand factor (VWF) antigen (Ag), ristocetine cofactor activity (RCo), collagen binding (CB), propeptide (pp), ristocetine induced platelet aggregation (RIPA), the rapid VWF activity assay VWF:GPIbM based on glycoprotein Ib (GPIb) binding to particles coated with G233V and

M239V mutants in the absence of ristocetin, the rapid VWF:GPIbR assay in the presence of ristocetine, and the responses to DDAVP of FVIII:C and VWF parameters to pick up secretion and/or clearance defects of VWF.


Results: The VWF:RCo/Ag, VWF:GPIbM/Ag and VWF:GPIbR ratios are completely normal (above 0.7) in all variants of VWD type 1 and Low VWF. The VWF:RCo/Ag, GPIbR/Ag and GPIbM/Ag ratios vary around the cut off level of 0.70 in VWD due to multimerization defect in the D3 domain and therefore diagnosed as either type 1 E or type 2E. The VWF:GPIbM/Ag and VWF:GPIbR/Ag ratios are pronounced decreased as compared to VWF:RCo/Ag and VWF:CB/Ag ratios in dominant VWD 2A and VWD 2B due to proteolytic loss of large and intermediate VWF multimers caused by VWF mutations in the A2 and A1 domain. VWD 2M due to loss of function mutation in the A3 domain is featured by decreased VWF:Rco/Ag ratio and normal VWF:CB/Ag ratio, whereas the VWF:GPIbR/Ag ratio (range 0.14-28) and the VWF:GPIbM/Ag ratio (range 0.32 to 0.36) were decreased indicating the need to retain the VWF:CB assay to make a correct diagnosis of VWD 2M. The introduction of the rapid VWF:GPIbM or VWF:GPIbR assays as compared to the classical VWF:RCo assay did change VWD type 2 into type 1 in about 10 to 12%. VWD type 1 due to a heterozygous mutation in the D1 domain is featured by persistence of proVWF as the cause of VWF secretion/multimerization and FVIII binding defect mimicking VWD type 3 together with decreased values for VWFpp, VWFpp/Ag ratios. The majority of 22 different missense mutations in the D3 domain are of type 1 or 2 E multimerization defect usually associated with an additional secretion defect (increased FVIII:C/VWF:Ag ratio) and or clearance defect (increased VWFpp/Ag ratio). The majority of VWF mutations in the D4 and C1 to C6 are VWD type 1 SD with smeary (1sm) or normal (1m) multimers with no or a minor clearance defect. The heterozygous S2179F mutation in the D4 domain is featured by VWD type 1 secretion and clearance (SCD).


Summary/Conclusion: A complete set of sensitive FVIII:C and VWF assays related to domain location of the molecular defect is mandatory for correct diagnosis and classification of VWD.


OMICS International Healthcare IT 2018 International Conference Keynote Speaker Arjun Panesar; Charlotte Summers photo

Charlotte Summers, BSc Psychology,

COO, Diabetes Digital Media

Charlotte is responsible for the creation and delivery of digital education programs with proven health outcomes and cost savings. With a background in psychology, Charlotte's passion and expertise lie in creating offline accountability and sustainable health behavioural change in a digital age.

Arjun Panesar, MEng Artificial Intelligence,

Co-founder, Diabetes Digital Media

Arjun has a decade of experience with intelligent health systems and big data. Holding a Masters in Artificial Intelligence from Imperial College London, Arjun's focus is transforming healthcare through empowering patients - through the use of real-world big data and genomics.



Program Topic Areas:

1. Diabetes, obesity, metabolic health

2. Digital Health

3. Nutritional guidelines and best practice


For the past few decades, diet and lifestyle programs for adults with type 2 diabetes have included recommendations to follow a low-fat diet, often using in-person programs. In

parallel, however, research has shown that carbohydrate-reduced diets may more effectively reduce body weight, improve glycemic control, and reduce hypoglycemic medications. Plus, online interventions have shown promise for encouraging these dietary changes. The Low Carb Program has combined these approaches, teaching a carbohydrate reduced, real-food way of eating to adults with type 2 diabetes supported by digital approaches enabling behaviour change and sustainable health improvements.

The goals of this talk are to:

(1) examine the preliminary efficacy of these carbohydrate-reduced digital interventions for reducing body weight, improving glycemic control, and reducing hypoglycemic medications in adults with type 2 diabetes.

(2) Highlight the efficacy of a digital intervention as a method of delivery and behavior change support. The presenters will talk about a commercially available digitally supported program that teaches a low-carbohydrate diet using online videos- and handout-based lessons, weight self-monitoring, dietary self-monitoring, digital social support groups, and medication management through the participants' own healthcare team. Results will be presented from a prospective longitudinal study. Overall, it is the presenters hope that the audience will be provided with new ways to think about diet and lifestyle interventions for adults with type 2 diabetes.

Learning Objectives:

- Learn how the Low Carb Program, a digital health intervention has been enabling adults with type 2 diabetes to implement a carbohydrate-reduced diet and lifestyle, in particular, understand how the components of this automated online low-carbohydrate program influence behaviour change

- Understand the potential impact of carbohydrate-reduced diets on weight loss, glycemic control, and medication reduction in adults with type 2 diabetes.



Type 2 diabetes has serious health consequences including blindness, amputation, stroke, and dementia, and its annual global costs are more than $800 billion. Although typically considered a progressive, nonreversible disease, some researchers and clinicians now argue that type 2 diabetes may be effectively treated with a carbohydrate-reduced diet.


Our objective was to evaluate the 1-year outcomes of a digitally delivered Low Carb Program (LCP), a nutritionally focused, 10-session educational intervention for glycemic control and weight loss for adults with type 2 diabetes. The program reinforces carbohydrate restriction using behavioral techniques including goal setting, peer support, and behavioral self-monitoring.


The study used a quasi-experimental research design comprised of an open-label, singlearm pre- and post-intervention using a sample of convenience. From adults with type 2 diabetes who had joined the program and had a complete baseline dataset, we randomly selected participants to be followed for 1 year (N=1000; mean age 56.1, SD 15.7, years; 59% (593/1000) women; mean HbA1c 7.8, SD 2.1, %; mean body weight 89.6, SD 23.1, kg; taking an average of 1.2 diabetes medications).


Of the 1,000 study participants, 708 (70.8%) individuals reported outcomes at 12 months, 672 (67.2%) completed at least 40% of the lessons, and 528 (52.8%) completed all lessons of the program. Of the 743 participants with a starting HbA1c at or above the type 2 diabetes threshold of 6.5%, 195 (26.2%) reduced their HbA1c to below the threshold while taking no glucose-lowering medications or just metformin. Of the participants who were taking at least one hypoglycemic medication at baseline, 40.4% (289/714) reduced one or more of these medications. Almost half (46.4%, 464/1000) of all participants lost at least 5% of their body weight. Overall, glycemic control and weight loss improved, especially for participants who completed all 10 modules of the program. For example, participants with elevated baseline HbA1c (≥7.5%) who engaged with all 10 weekly modules reduced their HbA1c from 9.2% to 7.1% (P<.001) and lost an average of 6.9% of their body weight (P<.001).


Especially for participants who fully engage, an online program that teaches a carbohydratereduced diet to adults with type 2 diabetes can be effective for glycemic control, weight loss, and reducing hypoglycemic medications.


Keynote Forum

Rogier Koning

Founder of Nobism, Spain

Keynote: Results of our First Patient Driven Research Month

Time : 12:35-13:15

OMICS International Healthcare IT 2018 International Conference Keynote Speaker Rogier Koning photo

Attending the Rudolf Steiner school until High school, educated me to always ask “why” to understand the reason behind it, to be critical and always view subjects from various sides. My personal live thought me that if you find a bull on the way , go around, under or if you have to go over it. Don’t let it stop you. After Highschool Ive studied at the TU Delft for a year changing afterwards to the Design Academy in Eindhoven and started soon my own company to build and design digital work. After moving to Spain Cluster Headaches started to change my life. This was a very big Bull on my road but my determination and stubbornness will bring to the other side of it.



Nobism is building a platform to support Patients, Leaders and their Advocates to collect data and use it do do research. We started by setting-up a Facebookgroup “Cluster Headache – Patient Driven Research”  We collect data about our personal symptoms and all the treatments we do to feel better.

We’ve started Collecting data in July and at the moment of this writing we have almost a 100 patient together collecting their data. Beginning of August we will share and analyse our first data set.

Patient Driven research is not the same as Medical research. Its a research based on statistics, symptoms dropping or rising and comparising of treatments taken.  Knowing patients do more than only medicines, we’ve added the option to collect data about all treatments we do,  to find the best ones available.

Most patient driven projects are setup NON-PROFIT and need to hold out their hands to get funding. Thats a hand you cannot byte. Nobism builds to create a place were patients can be COMMERCIAL like the rest of the world to generate the income for own research and Advocacy.

Nobism will start by supporting existing patient groeps in research. By adding functionality, we’ll transfer groups to nobism.

We aim to become WORLD LEADER in supporting and representing Patients in Research.